Danaher Corporation (NYSE:DHR) was downgraded from Buy to Hold by Ed Ridley with a price target reduction from $245 to $220. The company trades at a premium valuation with a forward non-GAAP P/E ratio of 26.30, but growth outlook for 2025 and 2026 remains below historic levels. Ridley expressed concern about limited visibility in China and diagnostic growth sustainability.

As a global innovator in life sciences and diagnostics, Danaher Corporation (NYSE:DHR) provides equipment, consumables, and services for biological medicines research and development. While DHR has investment potential, other AI stocks may offer greater upside with less downside risk. For a free report on an undervalued AI stock benefiting from Trump-era tariffs, visit the link provided.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Rothschild & Co. Redburn Downgrades Danaher Corporation (DHR) to Hold, Reduces PT